Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.38 |
| ▸ | BRAF | P15056 | 9/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | CPT2 | P23786 | 2/20 | 0.33 |
| ▸ | CPT1A | P50416 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17769781 | 1.00 | RAF1 (0.38) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL20550507 | 1.00 | RAF1 (0.38) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL20550506 | 0.96 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL17769637 | 0.96 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL17769814 | 0.96 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| Hydrochloric Acid SCHEMBL20550370 | 0.92 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| Hydrochloric Acid SCHEMBL17769614 | 0.92 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL20550448 | 0.91 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL17778543 | 0.91 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A | |
| SCHEMBL20550447 | 0.91 | RAF1 (0.37) | RAF1BRAFTRPV1CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
| EP-3220918-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079712-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RAF1 2196/4885BRAF 2837/4885TRPV1 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.